Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

January 24, 2022

CaroGen’s Hepatitis B vaccine recommended for $6.8M in federal funding

Photo | Contributed Bijan Almassian, president and CEO of CaroGen Corporation.

Farmington-based bioscience startup CaroGen said its immunotherapy vaccine that targets chronic Hepatitis B has been recommended for $6.8 million in federal funding by the U.S. Department of Defense.

CaroGen, which has been developing immunotherapies for cancer and infectious diseases at its lab space inside UConn’s Technology Incubation Program facility in Farmington, said that the U.S. Department of Defense Office of the Congressionally Directed Medical Research Programs recommended the funding award, which would enable further development of the company’s vaccine for the treatment of chronic hepatitis B.

The current clinical lead, CARG-201, and immunotherapies are being developed by collaborative efforts between CaroGen, Yale University and Albany Medical College scientists. To date, the program has received more $5 million in funding. 

The basis of CaroGen’s business is an immunotherapy concept developed by Dr. John Rose at Yale. CaroGen holds the exclusive rights to develop and commercialize the versatile virus-like vesicle (VLV) platform.

CaroGen is also working on immunotherapies for ovarian cancer with researchers at Wayne State University in Detroit and for colorectal cancer with researchers at UConn.

Sign up for Enews


Order a PDF